TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses
January 02, 2025 07:30 ET
|
SIGA Technologies Inc.
Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno Pharma Co., Ltd. engaged as exclusive...
Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced
December 10, 2024 16:00 ET
|
SIGA Technologies Inc.
Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study...
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024
November 07, 2024 16:05 ET
|
SIGA Technologies Inc.
Product Revenues for the Three and Nine months Ended September 30, 2024 were $9 million and $53 million, respectivelyReceived $122 Million of Procurement Orders from the U.S. Government in the Third...
SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results
October 31, 2024 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...
SIGA Enters into Exclusive License Agreement with Vanderbilt University for Novel Poxvirus Monoclonal Antibodies
October 22, 2024 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it...
SIGA Announces Agreement to Supply TPOXX® in Morocco
October 08, 2024 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it...
SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX®
August 21, 2024 16:00 ET
|
SIGA Technologies Inc.
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced a new contract...
Topline Results from PALM 007 Study of SIGA’s Tecovirimat in Treatment of Mpox Released
August 15, 2024 07:35 ET
|
SIGA Technologies Inc.
Preliminary analysis shows the study did not reach statistical significance on its primary endpoint of tecovirimat being superior to placebo in lesion resolution for all patientsResults suggest...
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2024
August 01, 2024 16:05 ET
|
SIGA Technologies Inc.
Generated Product Sales of $21 Million in the Second Quarter, and $45 Million in the Six Months Ended June 30, 2024Received $113 Million Procurement Order from U.S. Government for Oral TPOXX in...
SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results
July 25, 2024 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...